The cost of lung transplantation in the United States: How high is too high?
JTCVS Open · 2024-04 · 18 · 407-431
DOI: 10.1016/j.xjon.2024.01.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift JTCVS Open, 2024-04. Verfasst von Chelsea S Harris und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Duke University School of Medicine, Durham, NC. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Institutes of Health, National Center for Advancing Translational Sciences.
Abstract (Originalsprache)
Objectives
To identify patient and process factors that contribute to the high cost of lung transplantation (LTx) in the perioperative period, which may allow transplant centers to evaluate situations in which transplantation is most cost-effective to inform judicious resource allocation, avoid futile care, and reduce costs.
Methods
The MarketScan Research databases were used to identify 582 privately insured patients undergoing single or bilateral LTx between 2013 and 2019. The patients were subdivided into groups by disease etiology using the United Network of Organ Sharing classification system. Multivariable generalized linear models using a gamma distribution with a log link were fit to examine the associations between the etiology of lung disease and costs during the index admission, 3 months before admission, and 3 months after discharge.
Results
Our results indicate that the index admission contributed the most to the total transplantation costs compared to the 3 months before admission and after discharge. The regression-adjusted mean index hospitalization cost was 35% higher for patients with pulmonary vascular disease compared to those with obstructive lung disease ($527,156 vs $389,055). The use of extracorporeal membrane oxygenation, mechanical ventilation, and surgical complications in the post-transplantation period were associated with higher costs during the index admission. Surprisingly, age ≥55 was associated with lower costs during the index admission.
Conclusions
This analysis identifies pivotal factors influencing the high cost of LTx, emphasizing the significant impact of the index admission, particularly for patients with pulmonary vascular disease. These insights offer transplant centers an opportunity to enhance cost-effectiveness through judicious resource allocation and service bundling, ultimately reducing overall transplantation costs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Duke University School of Medicine, Durham, NC.
- Department of Surgery, Massachusetts General Hospital, Boston, Mass.
Förderung
- National Institutes of Health
- National Center for Advancing Translational Sciences
Zitieren
APA
Harris, C. S., Lee, H. J., Alderete, I. S., Halpern, S. E., Gordee, A., Jamieson, I., Scales, C., & Hartwig, M. G. (2024). The cost of lung transplantation in the United States: How high is too high?. JTCVS Open, 18, 407-431. https://doi.org/10.1016/j.xjon.2024.01.010
Vancouver
Harris CS, Lee HJ, Alderete IS, Halpern SE, Gordee A, Jamieson I, et al. The cost of lung transplantation in the United States: How high is too high?. JTCVS Open. 2024;18:407-431. doi:10.1016/j.xjon.2024.01.010
BibTeX
@article{Harris2024,
author = {Harris, Chelsea S and Lee, Hui-Jie and Alderete, Isaac S and Halpern, Samantha E and Gordee, Alexander and Jamieson, Ian and Scales, Charles and Hartwig, Matthew G},
title = {The cost of lung transplantation in the United States: How high is too high?},
journal = {JTCVS Open},
year = {2024},
volume = {18},
pages = {407--431},
doi = {10.1016/j.xjon.2024.01.010}
}
EUVIMED